Compound class:
Synthetic organic
Comment: ME-344 is an active metabolite of NV-128 [1], a novel flavonoid small molecule inhibitor of the mammalian target of rapamycin (mTOR).
|
|
No information available. |
Summary of Clinical Use ![]() |
A Phase 1/II clinical trial (NCT02100007) is evaluating the safety and tolerability of intravenous ME-344 in combination with topotecan (a drug approved for the treatment of small cell lung, ovarian and cervical cancers) for the treatment of relapsed/refractory small-cell lung cancer and platinum-refractory ovarian cancer. |